Clinical Model for the Prediction of Severe Liver Fibrosis in Adult Patients with Type II Diabetes Mellitus.

diabetes liver fibrosis pSWE

Journal

Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402

Informations de publication

Date de publication:
29 Jul 2022
Historique:
received: 13 06 2022
revised: 26 07 2022
accepted: 27 07 2022
entrez: 26 8 2022
pubmed: 27 8 2022
medline: 27 8 2022
Statut: epublish

Résumé

Background and Objectives: Non-alcoholic fatty liver disease (NAFLD)-related severe liver fibrosis is associated with a higher risk of progressing to decompensated cirrhosis and hepatic failure and developing NAFLD-related hepatocellular carcinoma (HCC), particularly in populations with diabetes. Our pilot study aims to evaluate the performances of various noninvasive methods in predicting liver fibrosis in a population of patients with diabetes and to establish a new scoring system for the prediction of severe fibrosis (>F3). Materials and Methods: A total of 175 patients with diabetes were enrolled for liver fibrosis evaluation. Using the degree of agreement (concordance) between a noninvasive score based on serum biomarkers (NAFLD fibrosis score) and point shear-wave elastography (pSWE) as the reference method, we generated receiver operating characteristic (ROC) curves and performed a multivariate analysis to predict severe liver fibrosis. Results: In our population of patients with diabetes, gamma-glutamyltransferase (GGT), age, body mass index (BMI), the homeostatic model assessment of insulin resistance (HOMA-IR), and glycosylated hemoglobin (HbA1C) were significant predictors for the diagnosis of the F3/F4 group (area under the ROC: 0.767, 0.743, 0.757, 0.772, and 0.7, respectively; p < 0.005 for all). Moreover, the combined composite score (the sum of GGT, age, BMI, HOMA index, and HbA1C) had the highest diagnostic performance at a cut-off value of 3 (AUROC—0.899; p < 0001). The sensitivity, specificity, negative predictive value (NPV), and positive predictive value (PPV) were 91.20%, 79%, 79%, and 89%, respectively, and 89% of patients were correctly classified as having severe liver fibrosis. In contrast with the Fibrosis 4 (FIB-4) score and the AST-to-platelet ratio index (APRI), the composite score had the best accuracy in discriminating advanced fibrosis. Conclusions: The proposed composite score had a reliable and acceptable diagnostic accuracy in identifying patients with diabetes at risk of having severe fibrosis using readily available laboratory and clinical data.

Identifiants

pubmed: 36010180
pii: diagnostics12081829
doi: 10.3390/diagnostics12081829
pmc: PMC9406388
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Clin Gastroenterol Hepatol. 2015 Apr;13(4):643-54.e1-9; quiz e39-40
pubmed: 24768810
Arch Intern Med. 1998 Sep 14;158(16):1789-95
pubmed: 9738608
World J Gastroenterol. 2019 Oct 28;25(40):6053-6062
pubmed: 31686762
Clin Gastroenterol Hepatol. 2021 Nov 9;:
pubmed: 34768009
J Diabetes Investig. 2021 Nov;12(11):2019-2027
pubmed: 33943028
Aliment Pharmacol Ther. 2007 Sep 15;26(6):821-30
pubmed: 17767466
Int J Low Extrem Wounds. 2021 Jun;20(2):98-103
pubmed: 33353439
Liver Int. 2017 Sep;37(9):1389-1396
pubmed: 28235154
Radiology. 2020 Aug;296(2):263-274
pubmed: 32515681
Transl Gastroenterol Hepatol. 2019 Oct 09;4:72
pubmed: 31728429
Obesity (Silver Spring). 2009 Sep;17(9):1696-701
pubmed: 19360015
Hepatology. 2009 Nov;50(5):1403-11
pubmed: 19670414
J Hypertens. 2020 Jun;38(6):982-1004
pubmed: 32371787
Semin Liver Dis. 2020 Nov;40(4):331-338
pubmed: 32526784
J Hepatol. 2011 Sep;55(3):666-672
pubmed: 21256907
J Hepatol. 2012 May;56(5):1171-1180
pubmed: 22245903
Eur J Radiol. 2014 Feb;83(2):268-72
pubmed: 24360231
J Clin Transl Hepatol. 2017 Sep 28;5(3):261-271
pubmed: 28936407
Gastroenterology. 2020 May;158(7):1999-2014.e1
pubmed: 32044314
Diabet Med. 2007 Jan;24(1):1-6
pubmed: 17227317
Hepatology. 2017 Nov;66(5):1486-1501
pubmed: 28586172
Am J Gastroenterol. 2009 Apr;104(4):861-7
pubmed: 19293782
Diabetes Care. 2007 Mar;30(3):734-43
pubmed: 17327353
J Viral Hepat. 2012 Feb;19(2):e212-9
pubmed: 22239521
J Obes Metab Syndr. 2022 Mar 30;31(1):1-3
pubmed: 35332113
Diabetes Care. 2022 Jan 1;45(Suppl 1):S17-S38
pubmed: 34964875
Diabetes Care. 2021 Feb;44(2):399-406
pubmed: 33355256
Dis Model Mech. 2009 May-Jun;2(5-6):231-7
pubmed: 19407331
Nat Rev Gastroenterol Hepatol. 2017 Jan;14(1):32-42
pubmed: 27729660
Diabetes Care. 2015 Jul;38(7):1347-55
pubmed: 25887357
PLoS One. 2020 Jan 15;15(1):e0227358
pubmed: 31940395
J Assoc Physicians India. 2009 Mar;57:205-10
pubmed: 19588648
Sci Rep. 2021 Dec 21;11(1):24372
pubmed: 34934162
Porto Biomed J. 2020 Dec 03;5(6):e101
pubmed: 33299950
J Hepatol. 2019 Oct;71(4):793-801
pubmed: 31279902
Hepatology. 2008 Feb;47(2):455-60
pubmed: 18038452
World J Gastroenterol. 2013 Aug 14;19(30):4841-9
pubmed: 23946588
J Clin Med. 2021 Aug 22;10(16):
pubmed: 34442032
Best Pract Res Clin Gastroenterol. 2017 Apr;31(2):129-141
pubmed: 28624101
Abdom Imaging. 2015 Apr;40(4):698-708
pubmed: 25690689
Exp Ther Med. 2020 Sep;20(3):2387-2391
pubmed: 32765720
Liver Int. 2021 Feb;41(2):261-270
pubmed: 32946642
Ultrasonography. 2020 Jan;39(1):52-59
pubmed: 31623416
Gastroenterology. 2005 Jun;128(7):1898-906
pubmed: 15940625
BMC Gastroenterol. 2006 Nov 02;6:33
pubmed: 17081293
Front Med (Lausanne). 2021 Apr 14;8:615978
pubmed: 33937277
Diabetologia. 1985 Jul;28(7):412-9
pubmed: 3899825
Sci Rep. 2022 Jan 7;12(1):283
pubmed: 34997159
World J Hepatol. 2015 Nov 8;7(25):2610-8
pubmed: 26557954
Antioxidants (Basel). 2021 Dec 29;11(1):
pubmed: 35052583
World J Gastroenterol. 2009 Nov 28;15(44):5525-32
pubmed: 19938190

Auteurs

Ovidiu Paul Calapod (OP)

Department of Gastroenterology, "Carol Davila" University of Medicine and Pharmacy, 050474 Bucharest, Romania.

Andreea Maria Marin (AM)

Department of Gastroenterology, "Carol Davila" University of Medicine and Pharmacy, 050474 Bucharest, Romania.

Anca Pantea Stoian (A)

Department of Diabetes, Nutrition and Metabolic Diseases, "Carol Davila" University of Medicine and Pharmacy, 050474 Bucharest, Romania.
"Prof. Dr. N. C. Paulescu" National Institute of Diabetes, Nutrition and Metabolic Diseases, 030167 Bucharest, Romania.

Carmen Fierbinteanu-Braticevici (C)

Department of Gastroenterology, "Carol Davila" University of Medicine and Pharmacy, 050474 Bucharest, Romania.
Emergency University Hospital of Bucharest, 050098 Bucharest, Romania.

Classifications MeSH